The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -2,220,719 | -1,785,058 | -9,466,966 |
| Preferred stock issued as compensation | 11,584 | 11,632 | 60,722 |
| Common stock issued as compensation and for services | 185,100 | 38,250 | 162,625 |
| Warrants granted to scientific advisory board | 123 | 135 | 679 |
| Depreciation | 131,016 | 130,752 | 735,536 |
| Amortization | 2,067 | 2,068 | 8,269 |
| Prepaid expenses | 19,130 | 14,709 | -60,596 |
| Other assets | -355 | -358 | -12,117 |
| Accounts payable | -183,480 | -57,301 | 82,824 |
| Accounts payable - related party | 28,089 | 79,687 | 101,417 |
| Accrued expenses | 15,338 | 331 | -236,498 |
| Net cash used in operating activities | -2,049,657 | -1,593,855 | -8,478,679 |
| Purchase of property and equipment | -1 | 84,317 | 56,964 |
| Net cash used in investing activities | 1 | -84,317 | -56,964 |
| Net proceeds from sale of common stock, net of issuance costs | 1,909,121 | - | - |
| Net proceeds from sale of common stock | - | 1,245,319 | 5,296,429 |
| Net proceeds from sale of common stock and common stock warrants, net of issuance costs | 5,410,723 | - | - |
| Net cash provided by financing activities | 6,074,525 | 1,245,319 | 5,296,429 |
| Net change in cash and cash equivalents | 4,024,869 | -432,853 | -3,239,214 |
| Cash and cash equivalents at beginning of period | 1,125,711 | 1,558,564 | 4,797,778 |
| Cash and cash equivalents at end of period | 5,150,580 | 1,125,711 | 1,558,564 |
NANOVIRICIDES, INC. (NNVC)
NANOVIRICIDES, INC. (NNVC)